---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-036395"
form_type: "8-K"
ticker: "BCAB"
cik: "0001826892"
company_name: "BioAtla, Inc."
filed_at: "2024-03-26T23:59:59+00:00"
generated_at: "2026-06-04T08:00:25.571791+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# BioAtla Q4 net loss $26.9M; cash $111.5M; multiple Phase 2 readouts on track for 2Q 2024

## Summary
- Net loss Q4 2023: $26.9M vs $27.6M Q4 2022; R&D expense $22.7M vs $21.9M.
- Cash $111.5M at year-end 2023; expected to fund operations into 2H 2025.
- CAB-CTLA-4 (BA3071) cleared DLT at 700 mg; Phase 2 monotherapy data due 2Q 2024.
- CAB-ROR2-ADC (BA3021) Phase 2 melanoma/SCCHN fully enrolled; data readouts in May.
- CAB-AXL-ADC (BA3011) UPS registration trial enrollment ~20 patients due April; FDA meeting 2H 2024.

## SEC filing metadata
- accession: 0000950170-24-036395
- form_type: 8-K
- ticker: BCAB
- cik: 0001826892
- company_name: BioAtla, Inc.
- filed_at: 2024-03-26T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1826892/000095017024036395/0000950170-24-036395-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1826892/000095017024036395/bcab-20240326.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-036395
- JSON: https://secwatch.observer/filing/0000950170-24-036395.json
- Plain text: https://secwatch.observer/filing/0000950170-24-036395.txt

## Key facts
- Earnings Releases
  BioAtla, Inc. reported financial results for fourth quarter and full year ended December 31, 2023.
  - Period: fourth quarter and full year ended December 31, 2023
  - Result: reported results
  source text: BioAtla, Inc. issued a press release announcing its financial results for the fourth quarter and fiscal year ended December 31, 2023
  evidence_url: https://www.sec.gov/Archives/edgar/data/1826892/000095017024036395/0000950170-24-036395-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.